The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10517 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax

Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34)

December 5, 2009 - 16:25 -- Kabogo Ndegwa
Author(s): 
Alvaro Mongui, Diana I. Angel, Gina Gallego, Claudia Reyes, Paola Martinez, Felipe Guhl, Manuel A. Patarroyo
Reference: 
Vaccine, Volume 28, Issue 2, 11 December 2009, Pages 415-421, doi:10.1016/j.vaccine.2009.10.034

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34.

Medical Condition: 

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.

December 3, 2009 - 12:11 -- Kabogo Ndegwa
Author(s): 
Manuel A. Giraldo, Gabriela Arevalo-Pinzon, Jose Rojas-Caraballo, Alvaro Mongui, Raul Rodriguez, Manuel A. Patarroyo
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 7-13, doi:10.1016/j.vaccine.2009.09.046.

In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. 

Medical Treatment: 

Priorities in research and development of vaccines against Plasmodium vivax malaria

December 3, 2009 - 12:05 -- Kabogo Ndegwa
Tags: 
Author(s): 
Graham V. Brown, Vasee S. Moorthy, Zarifah Reed, Kamini Mendis, Myriam Arévalo-Herrera, Pedro Alonso.
Reference: 
Vaccine, Volume 27, Issue 52, 9 December 2009, Pages 7228-7235, doi:10.1016/j.vaccine.2009.08.112

The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D). 

Medical Condition: 
Medical Treatment: 

Spurious Amplification of a Plasmodium vivax Small-Subunit RNA Gene by Use of Primers Currently Used To Detect P. knowlesi

December 3, 2009 - 09:28 -- Patrick Sampao
Author(s): 
Mallika Imwong, Naowarat Tanomsing, Sasithon Pukrittayakamee, Nicholas P. J. Day, Nicholas J. White, and Georges Snounou
Reference: 
Journal of Clinical Microbiology, December 2009, p. 4173-4175, Vol. 47, No. 12, doi:10.1128/JCM.00811-09

A nested primer set that targets one of the P. knowlesi small-subunit rRNA genes was validated for specificity and for sensitivity of detection of <10 parasite genomes.

Short communication: El Niño and variations in the prevalence of Plasmodium vivax and P. falciparum in Vanuatu

November 26, 2009 - 07:20 -- Kabogo Ndegwa
Author(s): 
M. Gilbert, R. Brindle
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 103, Issue 12, December 2009, Pages 1285-1287, doi:10.1016/j.trstmh.2008.10.048

As P. vivax is more prevalent in seasonal climates and P. falciparum in areas of more consistent rainfall, it is postulated that there will be a correlation between the ratio of vivax:falciparum and the El Niño Southern Oscillation (ENSO), which affects sea surface temperatures and rainfall.

Country: 
Natural Disaster: 

Nucleotide sequence polymorphism at the apical membrane antigen-1 locus reveals population history of Plasmodium vivax in Thailand

November 26, 2009 - 06:55 -- Patrick Sampao
Tags: 
Author(s): 
Chaturong Putaporntip, Somchai Jongwutiwes, Priscila Grynberg, Liwang Cui, Austin L. Hughes.
Reference: 
Infection, Genetics and Evolution, Volume 9, Issue 6, December 2009, Pages 1295-1300, doi:10.1016/j.meegid.2009.07.005.

Apical membrane antigen-1 is a candidate for inclusion in a vaccine for the human malaria parasite Plasmodium vivax.

Country: 
Medical Condition: 

Recurrence rate of vivax malaria in the Republic of Korea

November 26, 2009 - 06:53 -- Kabogo Ndegwa
Author(s): 
Ki Tae Moon, Young Keun Kim, Dong Hoon Ko, Inho Park, Dong Chun Shin, Changsoo Kim.
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 103, Issue 12, December 2009, Pages 1245-1249, doi:10.1016/j.trstmh.2008.10.023

In the Republic of Korea (ROK), military antimalarial chemoprophylaxis was initiated in 1997. Although chemoprophylaxis reduces malaria cases, long-term chemoprophylaxis could increase resistance. In this study, the recurrence rate of vivax malaria was investigated.

Country: 
Medical Condition: 

Pages

Subscribe to RSS - Plasmodium vivax